Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis

Fig. 5

miR-199a-5p regulated autophagy via the Sirt1/AMPK signaling pathway. a Western blotting analysis of the expression of Sirt1 and p-AMPK in control-MSCs and IPF-MSCs. b Western blotting analysis of the expression of Sirt1 and p-AMPK in control-MSCs treated with miR control, miR-199a-5p mimic, miR-199a-5p mimic + lenti-Sirt1, or miR-199a-5p mimic + AICAR. c Western blotting analysis of p62, Beclin, and LC3II/I expression in control-MSCs treated with miR control, miR-199a-5p mimic, miR-199a-5p mimic + lenti-Sirt1, or miR-199a-5p mimic +AICAR. d Representative images and quantitative analysis of SA-β-gal staining in control-MSCs treated with miR control, miR-199a-5p mimic, miR-199a-5p mimic + lenti-Sirt1, or miR-199a-5p mimic +AICAR. Scale bar = 200 μm. e Western blotting analysis of the expression of Sirt1 and p-AMPK in IPF-MSCs treated with miR control, miR-199a-5p inhibitor, miR-199a-5p inhibitor+Sirt1-siRNA, or miR-199a-5p inhibitor + Compound C. f Western blotting analysis of p62, Beclin, and LC3II/I expression level in IPF-MSCs treated with miR control, miR-199a-5p inhibitor, miR-199a-5p inhibitor+Sirt1-siRNA, or miR-199a-5p inhibitor + Compound C. g Representative images and quantitative analysis of SA-β-gal staining in IPF-MSCs treated with miR control, miR-199a-5p inhibitor, miR-199a-5p inhibitor + Sirt1-siRNA, or miR-199a-5p inhibitor + compound C. All data were obtained from at least three independent experiments and each error bar represents the mean ± SEM. Scale bar = 200 μm. ***p < 0.001

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512